CHARACTERIZING TUMOR EVOLUTION AND THERAPY RESISTANCE IN HIGH-RISK NEUROBLASTOMA

$1,311,596FY2020Defense Health AgencyDOD

Dana-Farber Cancer Institute, Inc.

Investigators

View source on USAspending →